KUALA LUMPUR: Duopharma Biotech Bhd
’s wholly owned subsidiary, Duopharma (M) Sdn Bhd (DMSB), has accepted a letter of award (LOA) from the government to supply insulin injection to the Ministry of Health’s (MOH) facilities.
In a filing with Bursa Malaysia today, the company said the contract, worth RM52.54 million, will run until Feb 5, 2028.
“The terms of the LOA will be formalised through the execution of a formal agreement between the government and DMSB at a later date. Until the formal agreement is executed, the LOA will continue to bind the parties.
“DMSB is required to deliver an irrevocable performance bond amounting to RM1.31 million within 30 days from the date of acknowledgement of acceptance of the LOA by DMSB,” it said.
Duopharma Biotech said the contract is expected to contribute positively to its net assets (NA), NA per share and earnings per share for the financial year ending Dec 31, 2026, and until the expiry of the contract.
DMSB is principally engaged in the manufacture, distribution, import and export of pharmaceutical products and medicines.- Bernama
